211 related articles for article (PubMed ID: 1456397)
1. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
2. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
3. Mass screening of neuroblastoma in Sapporo City, Japan.
Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
[TBL] [Abstract][Full Text] [Related]
4. Screening for neuroblastoma in the northern region of England. Laboratory aspects.
Seviour JA; McGill AC; Craft AW; Parker L; Bell S; Cole M; Smith J; Hawkins E; Brown J; Dale GA
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):332-6. PubMed ID: 1456399
[TBL] [Abstract][Full Text] [Related]
5. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
6. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
7. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
8. Cases of neuroblastoma missed by the mass screening programs.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J; Kawai T
Pediatr Res; 1989 Dec; 26(6):603-7. PubMed ID: 2602040
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening.
Tanaka M; Kigasawa H; Kato K; Ijiri R; Nishihira H; Aida N; Ohama Y; Tanaka Y
Pediatr Blood Cancer; 2010 Apr; 54(4):573-8. PubMed ID: 20049932
[TBL] [Abstract][Full Text] [Related]
10. Establishment of cut off values for vanillylmandelic acid and homovanillic acid in 24-hr urine accumulation during mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1987 Sep; 17(3):221-8. PubMed ID: 3669365
[TBL] [Abstract][Full Text] [Related]
11. Seasonal variations in vanillylmandelic acid and homovanillic acid in infants' urine.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1987 Jun; 17(2):151-5. PubMed ID: 3613139
[TBL] [Abstract][Full Text] [Related]
12. [Screening for neuroblastoma in infants aged 6 months. A method of testing].
Schrøder H; Møller J; Thomsen A; Skadborg R; Clausen N
Ugeskr Laeger; 1991 Dec; 153(51):3615-8. PubMed ID: 1776206
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma: the case for screening infants in North America.
Woods WG; Tuchman M
Pediatrics; 1987 Jun; 79(6):869-73. PubMed ID: 3588142
[TBL] [Abstract][Full Text] [Related]
14. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.
Nishi M; Takeda T; Hatae Y; Hanai J; Fujita K; Ichimiya H; Tanaka T
J Exp Clin Cancer Res; 2002 Mar; 21(1):73-8. PubMed ID: 12071533
[TBL] [Abstract][Full Text] [Related]
15. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.
Scriver CR; Gregory D; Bernstein M; Clow CL; Weisdorf T; Dougherty GE; Auray-Blais C; Giguère R; Lemieux B; Laberge C
CMAJ; 1987 May; 136(9):952-6. PubMed ID: 3105859
[TBL] [Abstract][Full Text] [Related]
17. Is the mass screening for neuroblastoma ineffective?
Nishi M; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hatae Y; Takeda T
J Exp Clin Cancer Res; 2003 Dec; 22(4):673-6. PubMed ID: 15053313
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
20. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
